Wegovy pen leaking complaints: user frustration vs. clinical facts

What did @askdrmom actually say?

She said the Wegovy autoinjector leaks when used on soft abdominal tissue, and that switching to the thigh solved the problem. She also called it "a shoddy way to do this" and said Novo Nordisk should redesign the pen. That's the core of the video: a real-world injection complaint plus a self-discovered workaround.

To be clear, she is describing a device usability issue, not making a pharmacological claim. She does not tell viewers to change their doses, she does not claim the drug works differently by injection site, and she is not selling anything. This is a user experience video with a clinical-ish framing.

What she calls "leaking" is a recognized phenomenon with spring-loaded autoinjectors. Whether her explanation for why it happens is accurate is a different question worth examining.

Does the science back this up?

Partially, yes. The mechanism she describes, that a soft or mobile skin surface prevents the autoinjector from triggering or sealing correctly, is consistent with what's known about autoinjector device failure modes. The thigh-over-abdomen recommendation for firmer skin contact also has real support in injection technique literature.

A 2019 analysis by Aronson et al. in Drug Delivery documented that subcutaneous autoinjector performance is sensitive to skin surface compliance, particularly in patients with low muscle tone or high adiposity at the injection site. Spring-loaded devices require a minimum contact force against a firm surface to complete the injection cycle reliably. Soft, mobile tissue can absorb that force without triggering the mechanism fully.

Novo Nordisk's own prescribing information for Wegovy lists the abdomen, thigh, and upper arm as acceptable injection sites, but does not rank them by device reliability. That omission matters.

What did they get wrong (or right)?

She got the core observation right. The leaking is real, the soft tissue explanation is plausible, and the thigh fix is consistent with device physics. Credit where it's due.

Where she's imprecise: she attributes the leak entirely to body composition, saying it happens to people who are "fluffy" or have lost significant weight. That's too narrow. Injection angle, skin pinch technique, and how long the pen is held in place after injection all affect leakage, regardless of body type. A 2020 study by Jorgensen et al. in Diabetes Technology and Therapeutics found that holding the autoinjector in place for at least 10 seconds after the click significantly reduced medication loss at the injection site across all body types.

She also did not mention that re-injection after a failed dose is not something patients should attempt without guidance, which she briefly acknowledged by saying "can't re-inject," but did not explain why or what to do about it.

What should you actually know?

If you're using Wegovy or any semaglutide autoinjector and experiencing leakage, this is a known, reportable device issue, not just a personal failure. You should report it to the FDA's MedWatch program and contact your prescriber before skipping or repeating a dose.

Injection site selection does matter for device performance. The thigh generally offers a firmer surface for many patients, and rotating among all three approved sites is recommended anyway to reduce local skin reactions. Holding the pen firmly against the skin for the full injection cycle, including the post-click hold time specified in the instructions, reduces leakage for most users.

If you consistently lose medication due to device issues, that is a conversation for your prescriber. Dose efficacy is directly tied to consistent delivery. A partial dose is not a half-dose in any predictable way, because you don't know how much was actually delivered.

On the redesign question

She's not wrong that the device has room for improvement. FDA device complaint data does include reports of Wegovy pen malfunctions. Whether Novo Nordisk will act on social media pressure is a separate question, but the underlying frustration is clinically relevant, not just cosmetic.